Bioasis Technologies Inc. and Aposense Enter into a Research Collaboration
Bioasis Technologies Inc. (OTCQB:BIOAF) has announced a research collaboration with Aposense Limited to enhance the delivery of siRNA therapies for neurological disorders. The partnership aims to leverage Bioasis’ xB3 platform, which enables the non-invasive delivery of genetic therapies across the blood-brain barrier. Recent data indicates that xB3 can effectively knock down the NOX4 gene in stroke models, signaling potential for treating severe conditions.
- Formation of collaboration with Aposense to advance siRNA therapy delivery.
- Recent data shows xB3 efficacy in gene knock-down related to stroke.
- None.
NEW HAVEN, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, is pleased to announce that it has formed a research collaboration with Aposense Limited (“Aposense”). Aposense is a highly innovative Israeli bio-pharmaceutical company, specializing in development of novel drugs, utilizing membrane electrical forces. The research collaboration will focus on the delivery of siRNA into the brain.
Dr. Deborah Rathjen, Bioasis’ Executive Chair said, “The non-invasive delivery of genetic therapies such as siRNA into the brain has proved challenging. Neurological diseases affect over a billion people worldwide and to address this challenge Bioasis has developed a revolutionary technology that delivers effective treatments across the blood-brain barrier. With the recent publication of data demonstrating efficacy associated with xB3-siRNA knock-down of the NOX4 gene in a model of stroke, we are pleased to have formed this collaboration with Aposense and we look forward to progressing the discovery and development of new siRNA-based drugs incorporating our xB3 platform, enabling the treatment of serious neurological conditions.”
“siRNA therapeutics for CNS disorders holds the potential to address devastating diseases of great unmet medical need, and an immediate expansion area for Aposense. Accordingly, we are thrilled to incorporate our vast know how in the design and delivery of siRNA-based drugs with the xB3 BBB delivery platform developed by Bioasis,” commented Yuval Gottenstein the CEO of Aposense.
Contacts
On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen
deborah@bioasis.us
+1 203 533 7082
Follow on:
Facebook
Instagram
LinkedIn
Twitter
BTI-CRP
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. For more information about the Company, please visit www.bioasis.us.
About Aposense Limited
Aposense is a highly innovative Israeli bio-pharmaceutical company, specializing in development of novel drugs, utilizing membrane electrical forces. Among others, Aposense developed a universal platform entitled Molecular Nano-Motors (MNMs) for the delivery of genetic drugs, such as siRNA, into cells. https://aposense.com/
Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact along with other statements containing the words “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FAQ
What is the recent collaboration involving Bioasis Technologies?
What technology is Bioasis using in its research?
What recent data supports Bioasis' xB<sup>3</sup> technology?
What potential impact does this collaboration have for Bioasis (BIOAF)?
